Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 8/20 | 0.60 |
| ▸ | TBXAS1 | P24557 | 8/20 | 0.55 |
| ▸ | PDE4A | P27815 | 1/20 | 0.54 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.54 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.54 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20601870 | 0.95 | CYP19A1 (0.66) | CYP19A1TBXAS1CYP11B1CYP11B2 | |
| SCHEMBL16684296 | 0.88 | TBXAS1 (0.64) | CYP19A1TBXAS1PDE4APDE4BPDE4C | |
| SCHEMBL6033876 | 0.82 | CYP19A1 (0.69) | CYP19A1TBXAS1CYP11B1CYP11B2 | |
| SCHEMBL20601853 | 0.82 | CYP19A1 (0.62) | CYP19A1TBXAS1CYP11B1CYP11B2 | |
| SCHEMBL306338 | 0.82 | CYP11B1 (0.73) | CYP19A1TBXAS1CYP11B1CYP11B2 | |
| SCHEMBL10674015 | 0.82 | CYP19A1 (0.59) | CYP19A1TBXAS1CYP11B1CYP11B2 | |
| SCHEMBL20623014 | 0.81 | TBXAS1 (0.62) | CYP19A1TBXAS1CYP11B1CYP11B2 | |
| SCHEMBL6668579 | 0.78 | KMT2A (0.74) | — | |
| SCHEMBL10674009 | 0.78 | CYP19A1 (0.60) | CYP19A1TBXAS1CYP11B1CYP11B2 | |
| SCHEMBL12639833 | 0.78 | CYP19A1 (0.68) | CYP19A1TBXAS1CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200181122-A1 | Degradable Imidazolium Oligomer and Polymer for Antimicrobial Applications | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2020-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200181122-A1 | Degradable Imidazolium Oligomer and Polymer for Antimicrobial Applications | NOD2, CFTR, PUF60 | CYP19A1 4646/4885TBXAS1 2982/4885PDE4A 3748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.